Candel Therapeutics (CADL) Gains from Investment Securities (2020 - 2025)

Candel Therapeutics has reported Gains from Investment Securities for 6 years, with the latest figure at $13.5 million in Q4 2025.

• Quarterly Gains from Investment Securities rose 131.81% year-over-year to $13.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.2 million (down 139.41% YoY) and the FY2025 annual result came in at -$8.2 million, down 139.41% from the prior year.
• Gains from Investment Securities grew to $13.5 million in Q4 2025 per CADL's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $13.5 million in Q4 2025 and troughed at -$14.9 million in Q1 2025.
• A 5-year average of $352052.6 and a median of -$369000.0 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities soared 9363.19% in 2024, then plunged 212485.71% in 2025.
• Over 5 years, Gains from Investment Securities stood at -$9.2 million in 2021, then jumped by 70.17% to -$2.7 million in 2022, then surged by 117.6% to $483000.0 in 2023, then surged by 1107.45% to $5.8 million in 2024, then soared by 131.81% to $13.5 million in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $13.5 million, -$1.1 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.